Maximizing treatment benefits for people with chronic kidney disease
Maximizing The Benefit of Therapy in CKD
['FUNDING_R01'] · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · NIH-11125769
This project looks at how common medicines work and how safe they are for adults with chronic kidney disease so doctors can use them more safely and effectively.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | NEW YORK UNIVERSITY SCHOOL OF MEDICINE (nih funded) |
| Locations | 1 site (NEW YORK, UNITED STATES) |
| Trial ID | NIH-11125769 on ClinicalTrials.gov |
What this research studies
This project looks at health records from many hospitals and clinics — covering roughly 25 million patients — to see how medicines perform for people with different levels of kidney function. It follows adults with CKD who take drugs like ACE inhibitors, ARBs, SGLT2 inhibitors, metformin, spironolactone, and statins to track benefits and side effects. The team also checks whether recommended monitoring (for example, urine albumin testing) is being done and is developing ways to add helpful alerts into electronic health records. The aim is to turn real-world data into clearer guidance so you and others with CKD get safer medicine choices.
Who could benefit from this research
Good fit: Adults aged 21 or older with chronic kidney disease or reduced kidney function, especially those taking ACE inhibitors, ARBs, SGLT2 inhibitors, metformin, spironolactone, or statins, are the main group studied.
Not a fit: People under 21, those without kidney disease, or individuals whose care is entirely outside the participating health systems are unlikely to be directly included or benefit immediately from this work.
Why it matters
Potential benefit: Could lead to safer, more effective medication choices and better monitoring for people with CKD, reducing side effects and complications.
How similar studies have performed: Large observational pharmacoepidemiology studies have previously uncovered medication risks and care gaps, and this project builds on a prior successful phase that analyzed over 5 million patients.
Where this research is happening
NEW YORK, UNITED STATES
- NEW YORK UNIVERSITY SCHOOL OF MEDICINE — NEW YORK, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: GRAMS, MORGAN ERIKA — NEW YORK UNIVERSITY SCHOOL OF MEDICINE
- Study coordinator: GRAMS, MORGAN ERIKA
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.